Drugs / SHetA2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04928508 | Jul 2022 → May 2026 overdue | cancer | University of Oklahoma | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHetA2 | “Phase 1 Trial of OK-1 (SHetA2) in Patients With Advanced or Recurrent Solid Tumors” NCT04928508 ↗ |
| Known as | OK-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04928508 ↗ |
| Modality | Small molecule | — CHEMBL7075 ↗ |
| Route | Oral | “OK-1 orally in the form of 50 mg capsules.” NCT04928508 ↗ |